TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participants aged ≥48 months to ≤ 51 months from preliminary study (NCT03147560) with sequential immunization history by Sabin IPV and bOPV.~* Parent/legal acceptable representative is willing and able to understand the protocol requirements and provide informed consent.~* ≥ 14 days interval between the last vaccination.~* Body temperature ≤ 37.2℃.~Exclusion Criteria:~* Known acute illness, severe chronic disease, acute exacerbation of chronic disease and fever.~* Known allergy to any constituent of the vaccine.~* Had 4 doses vaccination record of polio vaccine.~* Known impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin .~* Received non-specific immunoglobulin within 1 month.~* An acute illness with fever (temperature ≥ 37.3℃) or any infectious diseases.~* Patients with a well-diagnosed history of thrombocytopenia or other coagulation disorders that may cause contraindications for injection.~* Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the vaccine.

- Gender: ALL
- Minimum Age: 48 Months
- Maximum Age: 51 Months
- Healthy Volunteers: t

Study Arms:
- Group A(Sabin IPV+ bOPV+ bOPV+Sabin IPV) (Type: EXPERIMENTAL): Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 1 of preliminary study (NCT03147560).
- Group B(Sabin IPV+ Sabin IPV+ bOPV+bOPV) (Type: EXPERIMENTAL): Give the 4th doses of polio vaccine with bOPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
- Group C(Sabin IPV+ Sabin IPV+ bOPV+Sabin IPV) (Type: EXPERIMENTAL): Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
- Group D(Sabin IPV+ Sabin IPV+ Sabin IPV+bOPV) (Type: EXPERIMENTAL): Give the 4th doses of polio vaccine with bOPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.
- Group E(Sabin IPV+ Sabin IPV+ Sabin IPV+Sabin IPV) (Type: EXPERIMENTAL): Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mechanisms and Management of Infant Dysphagia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants with feeding-related aero-digestive symptoms~* ≤60 weeks PMA (both pre-term and full term)~* History of orally feeding ≥ 25% of least 50% of prescribed feeding volume~* Room air or supplemental oxygen of ≤1liter/minute (LPM)~Exclusion Criteria:~* Direct breast feeding exclusively~* Known genetic, metabolic or syndromic disease~* Neurological diseases such as Grade 3 or 4 intraventricular hemorrhage (IVH) or intracranial hemorrhage (ICH), moderate to severe perinatal asphyxia or stroke~* Craniofacial, airway or foregut malformations~* History of craniofacial, foregut, ears, nose and throat (ENT) or neurosurgery

- Gender: ALL
- Minimum Age: 38 Weeks
- Maximum Age: 60 Weeks
- Healthy Volunteers: f

Study Arms:
- Study (Type: ACTIVE_COMPARATOR): Eligible subjects (study) will undergo diagnostic VFSS in combination with manometry, either concurrent or sequential. They will have parental choice of preferred feeding therapy.
- Control (Type: NO_INTERVENTION): Eligible subjects who had VFSS alone with provider recommendations from the same single center.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least a 6 month history of physician diagnosed migraine and typically experiences 2-6 migraine attacks per month.~* Typically experiences moderate to severe migraine pain preceded by a mild pain phase.~* Differentiate between mild migraine pain and other headache types.~* Women of childbearing potential must be on adequate contraception.~Exclusion Criteria:~* Pregnant and/or nursing mother.~* History of cardiovascular disease.~* Uncontrolled hypertension.~* Basilar or Hemiplegic migraine.~* History of stroke or transient ischemic attacks (TIA).~* History of epilepsy or treated with anti-epileptics within past 5 years.~* Impaired hepatic or renal function.~* History of gastrointestinal bleeding or ulceration.~* Allergy or hypersensitivity to aspirin or any other NSAID.~* Allergy or hypersensitivity to triptans.~* Participated in an investigational drug trial in the previous 4 weeks.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- arm 1 (Type: EXPERIMENTAL): Treximet (sumatriptan/naproxen sodium)
- arm 2 (Type: PLACEBO_COMPARATOR): placebo to match

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects between ≥ 18 and ≤ 85 years old.~* Subjects who signed written, IRB approved, informed consent form.~* Subjects scheduled for urological or gynecological surgical procedures in which the patency of the ureter must be assessed by the surgeon during the procedure~Exclusion Criteria:~* Subjects with stage 4 or 5 Chronic Kidney Failure as evidenced by a GFR \<30 mL/min/1.73m2 (using the MDRD) or need for dialysis in the near future, or having only 1 kidney.~* Subjects with known severe hypersensitivity reactions to IC or other dyes including contrast agents.~* Known history of drug or alcohol abuse within 6 months prior to the time of screening visit.~* Subjects, as assessed by the Investigator, with conditions/concomitant diseases precluding their safe participation in this study (e.g. major systemic diseases).~* Unable to meet specific protocol requirements (e.g., scheduled visits) or subject is uncooperative or has a condition that could lead to non-compliance with the study procedures.~* Subject is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol;~* Subjects with life expectancy \< 6 months;~* Requirement for concomitant treatment that could bias primary evaluation.~* Subjects who are pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- HIGH DOSE (Type: EXPERIMENTAL): 48 subjects randomly treated with 5 mL of drug
- LOW DOSE (Type: EXPERIMENTAL): 48 subjects randomly treated with 2.5 mL of drug
- Saline (Type: PLACEBO_COMPARATOR): 96 subjects treated with 5 ml of saline than crossover to treatment arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult s (18 80 years) with HCC and who refused surgical resection~2. Tumour number not more than five and the largest tumour size not larger than 5.0 cm;~3. Ill defined lesions which are not easily detected on grey scale USG for lesion targeting.~4. Liver function status at Child Pugh class A or B;~5. East Coast Oncology Group (ECOG) performance status value 0 or 1;~6. No severe coagulopathy (e.g. platelets ≥50,000/ prothrombin time ratio ≥ 50%).~7. Available medical records and/or imaging studies.~Exclusion Criteria:~1. Presence of vascular invasion and extrahepatic metastases at pre procedure imaging study;~2. Ongoing anticoagulant treatment that cannot be stopped;~3. Combined TACE and ablation for a larger lesion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patients undergoing ablation for HCC (Type: EXPERIMENTAL): Pre-procedure CEUS will be performed on patients undergoing ablation followed by targeting of lesions for precise needle placement in the Kupffer phase. 2 hours post procedure USG with contrast will also be done for response assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~a. For participants with plaque psoriasis: i. Stable plaque psoriasis for at least 6 months ii. Moderate to severe disease iii. Candidate for phototherapy or systemic therapy b. Additional protocol-specified inclusion criteria apply for subjects with psoriatic arthritis, erythrodermic psoriasis, or generalized pustular psoriasis~Exclusion Criteria:~1. Guttate, inverse, or drug-induced psoriasis at Screening or Baseline~2. History of recent infection~3. Prior exposure to BMS-986165~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BMS-986165 (Type: EXPERIMENTAL): Given daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pain Relief During Repair of Postpartum Perineal Tears

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Gestational age \> 37 weeks~2. Uncomplicated pregnancy~3. Single vertex fetus~4. Normal vaginal delivery~5. Women who will accept to participate in the study~Exclusion Criteria:~1. Women received epidural analgesia~2. Women required episiotomy~3. Women with intact perineum~4. Operative vaginal delivery~5. Allergy to the used drugs

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lidocaine injection (Type: ACTIVE_COMPARATOR): 5 mL of 2% lidocaine anhydrous solution (Depocaine) will be injected slowly along the lines of the edges of the perineal tears after delivery, with frequent aspirations to avoid intravascular injection.
- lidocaine-prilocaine cream (Type: EXPERIMENTAL): 5-g dose of Lidocaine-prilocaine cream will be applied to the intact tissue around each tear for 5 minutes before suturing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* History of chronic HCV infection (≥ 6 months)~* HCV genotype 1, 2, 3, 4, 5, 6, or indeterminate~* Liver transplant ≥ 3 months prior to screening~* Male and nonpregnant/ non-lactating female individuals without cirrhosis or with compensated cirrhosis~Key Exclusion Criteria:~* History of clinically significant illness or any other medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol,~* Co-infection with HIV or hepatitis B virus~* Known hypersensitivity to study medication,~* Use of any prohibited concomitant medications as within with window before the Day 1 visit.~* De novo or recurrent hepatocellular carcinoma posttransplant~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL FDC for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Type II diabetes mellitus aged 19 years or older~* Subjects who performed Dual therapies (complex allowed) for one of the following, along with meals and exercise therapy~  1. Subjects who are receiving metformin ≥ 1000 mg/d and dapagliflozin 10 mg/d at the same dose for at least 8 weeks prior to the screening visit~ 2. Subjects who are receiving metformin ≥ 1000 mg/d and SGLT-2 inhibitor except for dapagliflozin at the same dose for at least 8 weeks prior to the screening visit~* Subjects with 7.0%≤HbA1c≤10.5% at screening visit~* Subjects with fasting plasma glucose ≤ 270mg/dL at screening visit~* Subjects with 18.5kg/m2≤BMI≤40kg/m2 at screening visit~Exclusion Criteria:~* Patients with type 1 diabetes, secondary diabetes, gestational diabetes, diabetic ketoacidosis, diabetic coma, pre-coma, lactic acidosis, and acute or chronic metabolic acidosis~* patients with Hypopituitarism or adrenal insufficiency, pulmonary infarction, severe pulmonary dysfunction and other hypoxemia~* Patients with severe infectious disease or severe traumatic systemic disorders~* End stage renal disease or dialysis patients~* Patients with Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption~* Subjects with Liver cirrhosis, chronic active hepatitis B or C, cholecystitis, acromegaly, asthma or major skin allergies

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Evogliptin 5mg group (Type: EXPERIMENTAL): Evogliptin 5mg/d + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d
- Evogliptin Placebo group (Type: PLACEBO_COMPARATOR): Evogliptin Placebo + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Primary osteoarthritis of knee (confirmed by American College of Rheumatology \[ACR\] criteria).~* Requirement of regular non-steroidal anti-inflammatory drug (NSAID) therapy.~Exclusion Criteria:~* Evidence of active gastrointestinal ulceration within 12 months prior to the screening visit or history of active gastrointestinal bleeding within the previous 5 years.~* Known hypersensitivity to analgesics, antipyretics, or NSAIDS (including celecoxib).~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes~* Treated with diet and exercise alone or with metformin for at least 3 months prior to screening~* BMI 27-45 kg/m\^2~* HbA1c between 7.0 % and 8.0 %~Exclusion Criteria:~* Treated with other oral anti-diabetic agents other than metformin within 3 months of screening~* Patients previously treated with AC2993~* Patients presently treated with insulin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo 0.01 mL (Type: PLACEBO_COMPARATOR): 2 week placebo lead-in followed by Placebo 0.01 mL
- Placebo 0.02 mL (Type: PLACEBO_COMPARATOR): 2 week placebo lead-in followed by Placebo 0.02 mL
- Placebo 0.03 mL (Type: PLACEBO_COMPARATOR): 2 week placebo lead-in followed by Placebo 0.03 mL
- Placebo 0.04 mL (Type: PLACEBO_COMPARATOR): 2 week placebo lead-in followed by Placebo 0.04 mL
- AC2993 2.5 mcg (Type: EXPERIMENTAL): 2 week placebo lead-in (0.01 mL) followed by AC2993 2.5 mcg; 0.01 mL
- AC2993 5.0 mcg (Type: EXPERIMENTAL): 2 week placebo lead-in followed by AC2993 5.0 mcg; 0.01 mL
- AC2993 7.5 mcg (Type: EXPERIMENTAL): 2 week placebo lead-in followed by AC2993 7.5 mcg; 0.03 mL
- AC2993 10.0 mcg (Type: EXPERIMENTAL): 2 week placebo lead-in period followed by AC2993 10.0 mcg; 0.04 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* COPD over 40 years of age (30 to 60% post-bronchodilator FEV1 predictive value)~* Patients under Double~* Patients under triple therapy (for 1 Mo prior Screening)~Exclusion Criteria:~* Pregnant or lactating women~* Patients experiencing a COPD exacerbation requiring use of systemic steroids and/or antibiotics, hospitalization~* concommitant diseases impacting feasibility or safety

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Glyco 25 (Type: EXPERIMENTAL): BDP/FF (400/24 daily)+ Glyco 25µg daily
- Glyco 50 (Type: EXPERIMENTAL): BDP/FF (400/24 daily)+ Glyco 50 µg daily
- Glyco 100 (Type: EXPERIMENTAL): BDP/FF (400/24 daily)+ Glyco 100µg daily
- BDP/FF 400/24 (Type: ACTIVE_COMPARATOR): BDP/FF 400/24

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. histologically proven uterine cervical cancer~2. squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the uterine cervix~3. one of the followings, 1)primary stage Ⅳb cervical cancer, 2)the first relapse or persistent cervical cancer after curative first line treatments, 3)the second relapse or persistent cervical cancer after curative second line treatments including radiation, systemic chemotherapy, hormonal therapy, or vaccination therapy for the first relapse~4. Patients may have been previously treated with less than 50 Gy of palliative radiation therapy~5. Patients have received no prior treatment or a certain interval must have elapsed from the last administration of previous treatments including palliative radiation therapy~6. one of the followings, 1)There is at least one metastatic lesion outside the pelvic cavity except paraaortic LN and/or inguinal LN, 2)There is no metastatic lesion outside the pelvic cavity except paraaortic LN and/or inguinal LN and some of the lesions have been irradiated, 3)All lesions are localized inside the pelvic cavity, and some of them have been irradiated~7. no prior surgical therapy for metastatic lesions of the lung or inside the pelvic cavity~8. no bilateral hydronephrosis~9. no prior chemotherapy including more than two platinum-containing regimens~10. no prior chemotherapy including taxane~11. age: 20 to75 years~12. PS: 0-2~13. ANC ≧1,500 /mm3, Plt≧10.0×104/mm3, T-bil≦1.5 mg/dl, GOT（AST）≦100IU/l, sCre ≦1.2 mg/dl, Ccr≧50ml/min in using the Cockcroft-Gault equation, and normal ECG~14. written informed consent~Exclusion Criteria:~1. patients who have some neurologically functional disorder~2. symptomatic CNS metastasis~3. hypersensitive to alcohol~4. active infection~5. HBs antigen positive~6. uncontrollable hypertension~7. history of myocardiac infarction within six months~8. unstable angina~9. uncontrollable diabetes~10. Patients with a concomitant or prior invasive malignancy (except intramucosal malignancy which are curable with local therapy) who have had any evidence of the disease within the last 5 years~11. women during pregnancy or breast-feeding~12. patients with psychiatric illness~13. patients who have been treated with the systemic steroids medication

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Drug: chemotherapy: Paclitaxel/Cisplatin
- 2 (Type: EXPERIMENTAL): Drug: chemotherapy: Paclitaxel/Carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete